Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
NCT00847223 · Lymphoma Study Association · PHASE2 · terminated · last registry update 2018-08-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Inefficiency of treatment” | – | Registry record, Lymphoma Study Association |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FNTA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-11-15Also stopped (terminated): M.D. Anderson Cancer Center, Fenretinide (4-HPR) + SCH66336 (NCT00102635)
- 2018-11-14Also stopped (withdrawn): M.D. Anderson Cancer Center, SCH 66336 (NCT00005030)
- 2018-10-25Phase 3 first posted: Eiger BioPharmaceuticals, Lonafarnib + Ritonavir (NCT03719313)
- 2018-07-02Results posted on the registry: National Cancer Institute (NCI), sorafenib tosylate + erlotinib hydrochloride (NCT00335764)
- 2018-05-24Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Lonafarnib + Ritonavir (NCT02511431)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision